RSS | Login | Register

VIMPAT INJECTION

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare VIMPAT INJECTION to:

Generic Name for VIMPAT INJECTION

Lacosamide 10mg/mL; soln for IV infusion.

Legal Classification:

Pharmacological Class for VIMPAT INJECTION

Sodium channel inactivator.

Manufacturer of VIMPAT INJECTION

UCB Inc.

Indications for VIMPAT INJECTION

Adjunct in partial-onset seizures, when oral administration is not feasible.

Adult dose for VIMPAT INJECTION

Oral soln: use calibrated measuring device. Inj: may give without diluting, or mix in appropriate diluent and give by IV infusion over 30–60min. For oral and inj: ≥17yrs: initially 50mg twice daily; may increase at weekly intervals by 100mg/day in 2 divided doses . Maintenance dose: 200–400mg/day. Renal impairment (CrCl≤30mL/min), ESRD, mild-moderate hepatic impairment: max 300mg/day. Consider supplemental dose (50%) after hemodialysis. Avoid abrupt cessation (withdraw over 1 week).

Children's dosing for VIMPAT INJECTION

<17yrs: not recommended.

Also:

VIMPAT

VIMPAT ORAL SOLUTION

Warnings/Precautions for VIMPAT INJECTION

Severe hepatic impairment: not recommended. Cardiac conduction disturbances (eg, 2^nd degree AV block). Severe cardiac disease (eg, myocardial ischemia, heart failure). Monitor for suicidal ideation, depression. Diabetic neuropathy. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for VIMPAT INJECTION

Caution with other drugs that cause PR prolongation.

Adverse Reactions for VIMPAT INJECTION

Dizziness, ataxia, diplopia, headache, GI upset, syncope; rare: multiorgan hypersensitivity reaction.

Notes for VIMPAT INJECTION

To enroll in the UCB AED Pregnancy Registry call (888) 537-7734.

How is VIMPAT INJECTION supplied?

Tabs—60
Oral soln—465mL
Single-use vials (20mL)—10

Related Disease:

Epilepsy

Seizure disorders

Phase 3 study of perampanel for the treatment of epilepsy

August 24, 2010

Eisai announced results from its Phase 3 study of perampanel for the treatment of partial seizures in patients with epilepsy.

FDA warns of aseptic meningitis risk with Lamictal

August 13, 2010

The FDA has informed healthcare professionals and patients that Lamictal (lamotrigine, from GlaxoSmithKline) can cause aseptic meningitis.

Oral solution formulation of Vimpat available

June 14, 2010

UCB announced that it has made available an oral solution formulation of Vimpat (lacosamide), an antiepileptic drug for the add-on treatment of partial-onset seizures in patients ≥17 years of age with epilepsy.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Lamictal XR approved as add-on therapy for primary generalized tonic-clonic seizures

February 01, 2010

The FDA has approved Lamictal XR (lamotrigine extended-release tablets, from GlaxoSmithKline) as a once daily, add-on therapy for epilepsy in patients ≥13 years of age with primary generalized tonic-clonic seizures.